CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug2481 Tezepelumab Wiki 0.71
drug520 Capillary and salivary sampling Wiki 0.71
drug1822 Placebo Wiki 0.04

Correlated MeSH Terms (10)


Name (Synonyms) Correlation
D001982 Bronchial Diseases NIH 0.71
D006969 Hypersensitivity, Immediate NIH 0.71
D012130 Respiratory Hypersensitivity NIH 0.71
D006967 Hypersensitivity, NIH 0.41
D001249 Asthma NIH 0.35
D007154 Immune System Diseases NIH 0.29
D008173 Lung Diseases, Obstructive NIH 0.24
D008171 Lung Diseases, NIH 0.18
D012140 Respiratory Tract Diseases NIH 0.17
D007249 Inflammation NIH 0.14

Correlated HPO Terms (4)


Name (Synonyms) Correlation
HP:0012393 Allergy HPO 0.41
HP:0002099 Asthma HPO 0.35
HP:0006536 Pulmonary obstruction HPO 0.24
HP:0002088 Abnormal lung morphology HPO 0.18

There are 2 clinical trials

Clinical Trials


1 Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19

Prospective study for clinical performance evaluation of COVID-19 diagnostic tests: detection of anti-SARS-CoV-2 antibodies by RDTs or ELISA (manual or automated), rapid diagnostic tests based on antigen detection, molecular or proteomic testing of SARS-CoV-2 (sensitivity, specificity, predictive values)

NCT04405492 SARS-CoV 2 COVID-19 Device: Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling. Device: Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling. Device: Capillary and salivary sampling

Primary Outcomes

Description: Tests based on detection of the virus SARS-CoV-2 (antigenic rapid tests, molecular tests, proteomic tests): sensibility and specificity compared to RT-PCR (Ct) in salivary samples and nasopharyngeal swabs from patients and cargivers included in the study Tests based on detection of human antibodies generated in response to infection (rapid immunodiagnostic tests, ELISA): sensibility and specificity compared to RT-PCR (Ct) and ELISA (antibody titer) in blood or serum from patients and cargivers included in the study

Measure: Clinical performance of several diagnostic tests : tests based either on detection of the virus SARS-CoV-2 or detection of human antibodies generated in response to infection

Time: Total duration of the study is 10 months

Secondary Outcomes

Description: Hospitalized patients, positive or suspected of SARS-CoV-2 infection are included in the study. Medical data related to COVID-19 infection will be recorded. Caregivers will be asked information about their health status related to a possible COVID-19 infection: symptoms if any, symptoms duration, severity.

Measure: Sensitivity and specificity of immunological, antigenic, molecular and proteomic tests according to symptom duration, stage of the disease: asymptomatic, ambulatory, hospitalized, ventilated

Time: Total duration of the study is 10 months

Description: At each visit, participants will be asked information about their health status and their contacts with COVID-19 patients. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Point-of-care devices will be tested during the visit.

Measure: Description of the incidence of infection among hospital caregivers, time to seroconversion according to clinical form, medium-term antibody persistence

Time: Caregivers will be included in the study for 9 months. After inclusion (Day 0), follow-up visits at Day 15, 1 Month, 3 Months, 6 Months, 9 Months will be done.

Description: Blood samples (capillary and venous) will be taken for serology testing from hospitalized patients, positive or suspected of SARS-CoV-2 infection and from hospital caregivers exposed to SARS-CoV-2. Participants will be asked information about their health status and medical data related to COVID-19 infection will be recorded.

Measure: Sensitivity and specificity of immunodiagnostic tests according to the sample used (serum and capillary blood) and according to the duration of the symptoms

Time: Total duration of the study is 10 months

Description: Blood samples (capillary and venous) will be taken for serology testing from hospitalized patients, positive or suspected of SARS-CoV-2 infection and from hospital caregivers exposed to SARS-CoV-2. Participants will be asked information about their health status and medical data related to COVID-19 infection will be recorded.

Measure: Sensitivity and specificity of antigenic rapid tests, molecular tests, proteomic tests according to the sample used (salivary samples or nasopharyngeal swabs) and according to the duration of the symptoms

Time: Total duration of the study is 10 months

Description: Two rapid tests (NG Biotech) allowing anti-SRAS-CoV-2 antibodies detection from a fingerpick blood sample and antigen detection from a salivary sample will be provided in 3 pharmacies of Ile de France. The inclusion of lay persons will be carried out in pharmacies by investigators of the recruiting centers (Bacteriology and Virology departments). After inclusion, one of the tests will be given to the participant for self-testing. After performing the test, the participant will complete a questionnaire to give a feedback on the test usability and the result obtained.

Measure: Suitability of rapid tests in view of its intended purpose for self-testing

Time: 4 months

2 Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19

Prospective study for clinical performance evaluation of COVID-19 diagnostic tests: detection of anti-SARS-CoV-2 antibodies by RDTs or ELISA (manual or automated), rapid diagnostic tests based on antigen detection, molecular or proteomic testing of SARS-CoV-2 (sensitivity, specificity, predictive values)

NCT04405492 SARS-CoV 2 COVID-19 Device: Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling. Device: Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling. Device: Capillary and salivary sampling

Primary Outcomes

Description: Tests based on detection of the virus SARS-CoV-2 (antigenic rapid tests, molecular tests, proteomic tests): sensibility and specificity compared to RT-PCR (Ct) in salivary samples and nasopharyngeal swabs from patients and cargivers included in the study Tests based on detection of human antibodies generated in response to infection (rapid immunodiagnostic tests, ELISA): sensibility and specificity compared to RT-PCR (Ct) and ELISA (antibody titer) in blood or serum from patients and cargivers included in the study

Measure: Clinical performance of several diagnostic tests : tests based either on detection of the virus SARS-CoV-2 or detection of human antibodies generated in response to infection

Time: Total duration of the study is 10 months

Secondary Outcomes

Description: Hospitalized patients, positive or suspected of SARS-CoV-2 infection are included in the study. Medical data related to COVID-19 infection will be recorded. Caregivers will be asked information about their health status related to a possible COVID-19 infection: symptoms if any, symptoms duration, severity.

Measure: Sensitivity and specificity of immunological, antigenic, molecular and proteomic tests according to symptom duration, stage of the disease: asymptomatic, ambulatory, hospitalized, ventilated

Time: Total duration of the study is 10 months

Description: At each visit, participants will be asked information about their health status and their contacts with COVID-19 patients. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Point-of-care devices will be tested during the visit.

Measure: Description of the incidence of infection among hospital caregivers, time to seroconversion according to clinical form, medium-term antibody persistence

Time: Caregivers will be included in the study for 9 months. After inclusion (Day 0), follow-up visits at Day 15, 1 Month, 3 Months, 6 Months, 9 Months will be done.

Description: Blood samples (capillary and venous) will be taken for serology testing from hospitalized patients, positive or suspected of SARS-CoV-2 infection and from hospital caregivers exposed to SARS-CoV-2. Participants will be asked information about their health status and medical data related to COVID-19 infection will be recorded.

Measure: Sensitivity and specificity of immunodiagnostic tests according to the sample used (serum and capillary blood) and according to the duration of the symptoms

Time: Total duration of the study is 10 months

Description: Blood samples (capillary and venous) will be taken for serology testing from hospitalized patients, positive or suspected of SARS-CoV-2 infection and from hospital caregivers exposed to SARS-CoV-2. Participants will be asked information about their health status and medical data related to COVID-19 infection will be recorded.

Measure: Sensitivity and specificity of antigenic rapid tests, molecular tests, proteomic tests according to the sample used (salivary samples or nasopharyngeal swabs) and according to the duration of the symptoms

Time: Total duration of the study is 10 months

Description: Two rapid tests (NG Biotech) allowing anti-SRAS-CoV-2 antibodies detection from a fingerpick blood sample and antigen detection from a salivary sample will be provided in 3 pharmacies of Ile de France. The inclusion of lay persons will be carried out in pharmacies by investigators of the recruiting centers (Bacteriology and Virology departments). After inclusion, one of the tests will be given to the participant for self-testing. After performing the test, the participant will complete a questionnaire to give a feedback on the test usability and the result obtained.

Measure: Suitability of rapid tests in view of its intended purpose for self-testing

Time: 4 months


No related HPO nodes (Using clinical trials)